Evotec SE (XTER:EVT) Accounts Payable : €99.1 Mil (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Evotec SE Accounts Payable?

Evotec SE's Accounts Payable for the quarter that ended in Mar. 2024 was €99.1 Mil.

Evotec SE's quarterly Accounts Payable increased from Sep. 2023 (€96.8 Mil) to Dec. 2023 (€134.3 Mil) but then declined from Dec. 2023 (€134.3 Mil) to Mar. 2024 (€99.1 Mil).

Evotec SE's annual Accounts Payable increased from Dec. 2021 (€72.6 Mil) to Dec. 2022 (€97.3 Mil) and increased from Dec. 2022 (€97.3 Mil) to Dec. 2023 (€134.3 Mil).

Evotec SE Accounts Payable Historical Data

The historical data trend for Evotec SE's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Accounts Payable Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

31.32

42.55

72.60

97.28

134.32

Evotec SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															-	106.04	96.77	134.32	99.15

Evotec SE Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Evotec SE Accounts Payable Related Terms

Thank you for viewing the detailed overview of Evotec SE's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (XTER:EVT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Executives

Dr. Werner Lanthaler

Board of Directors

Evotec SE (XTER:EVT) Headlines

From GuruFocus

Unveiling the Dividend Performance of EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND (EVT)

By GuruFocus Research • 09-21-2023

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 01-22-2024

Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution

By PRNewswire PRNewswire • 01-15-2021

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 10-20-2023